SCHEMBL2846573

SCHEMBL2846573

C[Si](C)(C)O[Si](C)(CCC1CCC2OC2C1)O[Si](C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101898 0.94 PTGS1 (0.30) PTGS1PTGS2
SCHEMBL7509227 0.91
SCHEMBL31337051 0.88 PTGS1 (0.34) PTGS1PTGS2
SCHEMBL15146790 0.88 PTGS1 (0.31) PTGS1PTGS2
SCHEMBL30831373 0.86 PTGS1 (0.32) PTGS1PTGS2
SCHEMBL5162214 0.86 PTGS1 (0.34) PTGS1PTGS2
SCHEMBL11075346 0.86 PTGS1 (0.32) PTGS1PTGS2
SCHEMBL1261863 0.86 PTGS1 (0.32) PTGS1PTGS2
SCHEMBL26726946 0.85
SCHEMBL16886919 0.85 PTGS1 (0.31) PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240191078-A1 ULTRAVIOLET-RAY-CURABLE COMPOSITION AND USE THEREOF DOW TORAY CO LTD (JP) 2024-06-13 US claimed
US-20240174889-A1 ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF DOW TORAY CO LTD (JP) 2024-05-30 US claimed
WO-2022203042-A1 ULTRAVIOLET-RAY-CURABLE COMPOSITION AND USE THEREOF ダウ・東レ株式会社 2022-09-29 WO claimed
WO-2022202498-A1 ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF ダウ・東レ株式会社 2022-09-29 WO claimed
WO-2022102626-A1 ULTRAVIOLET RAY CURABLE COMPOSITION AND APPLICATIONS THEREOF ダウ・東レ株式会社 2022-05-19 WO claimed
US-8975357-B2 Silicone modified fatty acids, method of preparation and usage thereof NATURA INOVACAO E TECNOLOGIA DE PRODUTOS LTDA. (BR) 2015-03-10 US claimed
EP-2620464-B1 Silicone modified fatty acids, method of preparation and usage thereof NATURA INOVAC O E TECNOLOGIA DE PRODUTOS LTDA (BR) 2014-12-10 EP claimed
US-8846843-B2 Silicone modified fatty acids, method of preparation and usage thereof MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2014-09-30 US claimed
EP-2473550-B1 SILICONE MODIFIED FATTY ACIDS, METHOD OF PREPARATION AND USAGE THEREOF MOMENTIVE PERFORMANCE MAT INC (US) 2014-05-07 EP claimed
US-20130317105-A1 SILICONE MODIFIED FATTY ACIDS, METHOD OF PREPARATION AND USAGE THEREOF NATURA INOVACAO E TECNOLOGIA DE PRODUTOS LTDA. (BR) 2013-11-28 US claimed
EP-2620464-A1 Silicone modified fatty acids, method of preparation and usage thereof Momentive Performance Materials Inc. (US) 2013-07-31 EP claimed
US-20100040570-A1 SILICONE MODIFIED FATTY ACIDS, METHOD OF PREPARATION AND USAGE THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2010-02-18 US claimed
US-20260022202-A1 UV-CURABLE COMPOSITION AND USE THEREOF DOW TORAY CO LTD (JP) 2026-01-22 US disclosed
US-20250368774-A1 ULTRAVIOLET-CURABLE COMPOSITION AND USE THEREOF DOW TORAY CO LTD (JP) 2025-12-04 US disclosed
WO-2025058306-A1 EPOXY RESIN COMPOSITION FOR MOLDING 주식회사 케이씨씨 2025-03-20 WO disclosed
WO-2025058307-A1 EPOXY RESIN COMPOSITION FOR MOLDING 주식회사 케이씨씨 2025-03-20 WO disclosed
US-20080287562-A1 Stable cationically crosslinkable/polymerizable dental composition with a high filler content RHODIA CHIMIE (FR) 2008-11-20 US disclosed
US-20080064832-A1 Cationically curable silicone compositions based on colloidal silica and anti-mist/anti-fouling hard coatings formed therefrom RHODIA CHIMIE (FR) 2008-03-13 US disclosed
US-7247660-B2 Dental composition based on silicone crosslinkable by cation process RHODIA CHIMIE (FR) 2007-07-24 US disclosed
US-20070149636-A1 Dental composition based on silicone crosslinkable by cation process FRANCES JEAN-MARC 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317105-A1 SILICONE MODIFIED FATTY ACIDS, METHOD OF PREPARATION AND USAGE THEREOF ASAH1, FASN, ASAH2 PTGS1 905/4885PTGS2 864/4885
US-20080287562-A1 Stable cationically crosslinkable/polymerizable dental composition with a high filler content RFC1, RFC2, HNRNPC PTGS1 1535/4885PTGS2 1393/4885
US-20100040570-A1 SILICONE MODIFIED FATTY ACIDS, METHOD OF PREPARATION AND USAGE THEREOF FASN, ELOVL5, SCD5 PTGS1 700/4885PTGS2 662/4885
US-20260022202-A1 UV-CURABLE COMPOSITION AND USE THEREOF IDUA, SEM1, ARSA PTGS1 2446/4885PTGS2 2894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.